Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Sees Significant Decline in Short Interest

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 81,400 shares, a drop of 19.2% from the November 30th total of 100,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Newron Pharmaceuticals Price Performance

OTCMKTS NWPHF remained flat at $9.36 on Friday. Newron Pharmaceuticals has a 1-year low of $9.10 and a 1-year high of $12.00. The company has a fifty day moving average of $9.36 and a 200-day moving average of $9.92.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea.